234 related articles for article (PubMed ID: 24097273)
1. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
Lee SH; Byun SS; Lee SJ; Kim KH; Lee JY
Int Urol Nephrol; 2014 Mar; 46(3):523-9. PubMed ID: 24097273
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
[TBL] [Abstract][Full Text] [Related]
4. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
[TBL] [Abstract][Full Text] [Related]
5. [A Crossover Comparison Study on Lower Urinary Tract Symptoms with Overactive Bladder Secondary to Benign Prostatic Hyperplasia: Naftopidil versus Tamsulosin with Solifenacin].
Utsunomiya N; Matsumoto K; Tsunemori H; Muguruma K; Kawakita M; Kamiyama Y; Kanamaru S; Ito N; Tsukazaki H; Shirahase T; Takahashi T
Hinyokika Kiyo; 2016 Jul; 62(7):341-7. PubMed ID: 27569351
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
7. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
8. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
9. Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
Lee YS; Lee KS; Kim JC; Hong S; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK
Int J Clin Pract; 2014 Dec; 68(12):1496-502. PubMed ID: 25284747
[TBL] [Abstract][Full Text] [Related]
10. Clinical efficacy and safety of imidafenacin as add-on treatment for persistent overactive bladder symptoms despite α-blocker treatment in patients with BPH: the ADDITION study.
Takeda M; Nishizawa O; Gotoh M; Yoshida M; Takahashi S; Masumori N
Urology; 2013 Oct; 82(4):887-93. PubMed ID: 23953605
[TBL] [Abstract][Full Text] [Related]
11. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
[TBL] [Abstract][Full Text] [Related]
12. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.
Ko K; Yang DY; Lee WK; Kim SW; Moon du G; Moon KH; Park NC; Park JK; Son HC; Lee SW; Hyun JS; Park K
Korean J Urol; 2014 Sep; 55(9):608-14. PubMed ID: 25237463
[TBL] [Abstract][Full Text] [Related]
13. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Am J Mens Health; 2016 Mar; 10(2):157-63. PubMed ID: 26186951
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial.
van Kerrebroeck P; Chapple C; Drogendijk T; Klaver M; Sokol R; Speakman M; Traudtner K; Drake MJ;
Eur Urol; 2013 Dec; 64(6):1003-12. PubMed ID: 23932438
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study.
Athanasopoulos A; Gyftopoulos K; Giannitsas K; Fisfis J; Perimenis P; Barbalias G
J Urol; 2003 Jun; 169(6):2253-6. PubMed ID: 12771763
[TBL] [Abstract][Full Text] [Related]
18. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
[TBL] [Abstract][Full Text] [Related]
19. Can we decide the optimal initial treatment for male lower urinary tract symptoms patients with overactive bladder by the most bothersome symptom? A randomized, prospective, open-label study.
Yun JH; Kim JH; Kim JH; Lee SW; Yang HJ; Doo SW; Yang WJ
Urol Int; 2014; 93(3):338-43. PubMed ID: 25171502
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction.
Ichihara K; Masumori N; Fukuta F; Tsukamoto T; Iwasawa A; Tanaka Y
J Urol; 2015 Mar; 193(3):921-6. PubMed ID: 25254938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
